Robert Ross
Präsident bei SURFACE ONCOLOGY, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Robert Ross
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Präsident | - | - |
Direktor/Vorstandsmitglied | 01.04.2021 | - | |
Vorstandsvorsitzender | 01.04.2021 | - | |
Technik-/Wissenschafts-/F&E-Leiter | 01.10.2016 | 01.04.2021 | |
XILIO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 16.06.2022 | - |
Independent Dir/Board Member | 16.06.2022 | - | |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 03.09.2020 | - |
Karriereverlauf von Robert Ross
Ehemalige bekannte Positionen von Robert Ross
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01.10.2012 | 01.10.2016 |
Ausbildung von Robert Ross
Stanford University | Undergraduate Degree |
Harvard Medical School | Graduate Degree |
Columbia University College of Physicians & Surgeons | Graduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Director/Board Member | 3 |
Graduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Robert Ross
- Erfahrung